NCT03955276

An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)

An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies and Poor Prognoses (I-PREDICT Heme)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 13 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular mutation profile will then be matched to existing, FDA-approved, targeted agents or to existing clinical trials using investigational agents for treatment of patients with incurable hematologic malignancies for whom no effective standard therapy exists or who have either exhausted or are intolerant of standard options.

Conditions

• Hematologic Cancer

Interventions

Type	Name	Description
OTHER	Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)	Biologically targeted matched treatment (chosen by treating physician)

Timeline

• Start date: 2019-02-07
• Primary completion: 2020-11-20
• Completion: 2021-01-13
• First posted: 2019-05-20
• Last updated: 2022-02-15

Locations

1 site across 1 country: United States